BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cemiplimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cemiplimab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03951831-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT03951831)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: REGN2810 Followed by Chemoimmunot
 herapy for Newly Metastatic Hormone-sensitive Prostate Cancer\nEstimated p
 rimary completion: November 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT03951831
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04989946-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT04989946)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: Androgen Deprivation\, With or 
 Without pTVG-AR\, and With or Without T-Cell Checkpoint Blockade\, in Pati
 ents With Newly Diagnosed\, High-Risk Prostate Cancer\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04989946
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06623656-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06623656)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Preo
 perative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC\nEstimated 
 primary completion: December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06623656
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06088771-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT06088771)
DESCRIPTION:Cemiplimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable
  NSCLC\nEstimated primary completion: 1 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06088771
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04315701-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT04315701)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A PD-1 Checkpoint Inhibitor (Cemi
 plimab) for High-Risk Localized\, Locally Recurrent\, or Regionally Advanc
 ed Skin Cancer\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04315701
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731270-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06731270)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Dicl
 ofenac for the Treatment of Patients With Metastatic Non-small Cell Lung C
 ancer on Single Agent Immunotherapy\nEstimated primary completion: 1 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06731
 270
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608291-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT05608291)
DESCRIPTION:Cemiplimab\, phase 3\, Melanoma.\nStudy: A Trial to See if the 
 Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab f
 or Preventing or Delaying Melanoma From Coming Back After it Has Been Remo
 ved With Surgery\nEstimated primary completion: 15 January 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05608291
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860815-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06860815)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Cemiplimab and Transarterial Radi
 oembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed 
 Metastatic Breast Cancer\nEstimated primary completion: 30 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06860815
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07422363-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT07422363)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: Testing the Combination of Anti-c
 ancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Pa
 tients With Recurrent Glioblastoma\nEstimated primary completion: 28 Febru
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0742
 2363
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246916-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT06246916)
DESCRIPTION:Cemiplimab\, phase 3\, Melanoma.\nStudy: A Study With Combinati
 ons of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Adva
 nced or Metastatic Melanoma (Harmony Head-to-Head)\nEstimated primary comp
 letion: 22 March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06246916
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04387084-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT04387084)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: Short-term Fasting Prior to PD-1/
 PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy\nEst
 imated primary completion: 31 March 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04387084
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06171750-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT06171750)
DESCRIPTION:Cemiplimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors\nEstimate
 d primary completion: April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06171750
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05259709-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT05259709)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: A Study of ImmunoPet Imaging Usin
 g 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With 
 Cemiplimab\nEstimated primary completion: 29 April 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05259709
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06923761-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT06923761)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: EMITT-1 (ERAP Mediated Immunope
 ptidome Targeting Trial - 1)\nEstimated primary completion: 30 April 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06923761
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05961709-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT05961709)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: The Phoenix Trial: Phase II Trial
  of Cemiplimab for the Non-operative Management of Localized dMMR Colon Ca
 ncer\nEstimated primary completion: 30 April 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05961709
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06826768-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT06826768)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: A Ph Ib Study of REGN5678 Plus Ce
 miplimab in Patients With mCRPC\nEstimated primary completion: 1 May 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06826768
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03564340-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT03564340)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: Study of REGN4018 (Ubamatamab) 
 Administered Alone or in Combination With Cemiplimab in Adult Patients Wit
 h Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+)
  Cancers\nEstimated primary completion: 10 May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03564340
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448026-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06448026)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Cemiplimab and Cetuximab Prior Sa
 lvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Orop
 haryngeal Squamous Cell Carcinoma\nEstimated primary completion: 15 May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06448026
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722523-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT04722523)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: A Study of Cemiplimab With Chemot
 herapy and Immunotherapy in People With Head and Neck Cancer\nEstimated pr
 imary completion: 20 June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04722523
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988074-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT04988074)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Trial of Cemiplimab\, or Cemip-Ch
 emo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca\nEstimated
  primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04988074
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06444880-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06444880)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Phase II Trial of Ubamatamab Alon
 e or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient 
 Malignancies\nEstimated primary completion: 31 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06444880
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908304-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT06908304)
DESCRIPTION:Cemiplimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment
  in Advanced/Metastatic NSCLC\nEstimated primary completion: 31 July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06908304
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865339-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06865339)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Thor
 acic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced No
 n-Small Cell Lung Cancer\nEstimated primary completion: August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06865339
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06594991-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06594991)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: A Study of Fianlimab\,
  Cemiplimab\, and Ipilimumab in People With Melanoma\nEstimated primary co
 mpletion: September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06594991
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04253964-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT04253964)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pilo
 t Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell 
 Lung Cancer Patients Treated With Chemo/Immunotherapy\nEstimated primary c
 ompletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04253964
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785767-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Cemiplimab: Phase 2/3 readout est. (NCT05785767)
DESCRIPTION:Cemiplimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemipli
 mab Alone is More Effective for Adult Participants With Advanced Non-Small
  Cell Lung Cancer (NSCLC)\nEstimated primary completion: 28 September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05785767
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03233139-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT03233139)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: Safety and Pharmacokinetics of Ce
 miplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Ja
 panese Adult Patients With Advanced Malignancies\nEstimated primary comple
 tion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03233139
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07147231-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT07147231)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: Testing the Effectiveness of th
 e Anti-cancer Drug Pidnarulex (CX-5461)\, in Combination With Another Anti
 -cancer Drug Cemiplimab (REGN2810)\, in Treating Refractory Microsatellite
  Stable Colorectal Cancer\nEstimated primary completion: 30 September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07147231
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05208944-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT05208944)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: THIO
  Sequenced With Cemiplimab in Advanced NSCLC\nEstimated primary completion
 : 30 September 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05208944
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264673-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07264673)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ra
 ndomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintena
 nce Therapy in ctDNA Positive NSCL. The Cemited Study.\nEstimated primary 
 completion: October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07264673
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05574101-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271006
DTEND;VALUE=DATE:20271007
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT05574101)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A Study of Radiation Therapy and 
 Cemiplimab for People With Skin Cancer\nEstimated primary completion: 6 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 574101
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03972657-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT03972657)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: A Trial to Find Out if REGN5678
  (Nezastomig) is Safe and How Well it Works Alone or in Combination With C
 emiplimab for Adult Participants With Metastatic Castration-Resistant Pros
 tate Cancer and Other Tumors\nEstimated primary completion: 15 November 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03972657
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06980038-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271124
DTEND;VALUE=DATE:20271125
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06980038)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Testing Whether Cemiplimab (REGN2
 810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN
 2810) Alone in Patients With Stage III-IV Head and Neck Cancer\nEstimated 
 primary completion: 24 November 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06980038
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449313-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06449313)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non
 -small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features\nEs
 timated primary completion: December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06449313
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06743581-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cemiplimab: Phase na readout est. (NCT06743581)
DESCRIPTION:Cemiplimab\, phase na\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell L
 ung Cancer\nEstimated primary completion: December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06743581
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07450183-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07450183)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Peri
 operative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High P
 D-L1\nEstimated primary completion: 1 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07450183
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03491683-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT03491683)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: INO-5401 and INO-9012 Delivered
  by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newl
 y-Diagnosed Glioblastoma (GBM)\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03491683
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03565783-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT03565783)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Cemiplimab in Treating Patients W
 ith Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous 
 Cell Cancer Before Surgery\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03565783
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06528769-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06528769)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Study of All-Trans Retinoic Acid 
 (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma\nEstimated 
 primary completion: 31 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06528769
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616584-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cemiplimab: Phase 2/3 readout est. (NCT06616584)
DESCRIPTION:Cemiplimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 ding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With 
 Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platin
 um Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06616584
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887088-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06887088)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: Encorafenib and biNime
 tinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant me
 lanOma and Symptomatic Brain Metastases\nEstimated primary completion: Jan
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 87088
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05704634-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT05704634)
DESCRIPTION:Cemiplimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-recept
 or Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for 
 Patients With Non-small Cell Lung Cancer.\nEstimated primary completion: 1
  January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemipl
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05704634
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03969004-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280107
DTEND;VALUE=DATE:20280108
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT03969004)
DESCRIPTION:Cemiplimab\, phase 3.\nStudy: Study of Adjuvant Cemiplimab Vers
 us Placebo After Surgery and Radiation Therapy in Patients With High Risk 
 Cutaneous Squamous Cell Carcinoma\nEstimated primary completion: 7 January
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0396900
 4
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05557591-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280126
DTEND;VALUE=DATE:20280127
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT05557591)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Tr
 ial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab 
 Works and How Safe the Combination is in Adults With Advanced Non-small Ce
 ll Lung Cancer (EMPOWERVAX Lung 1)\nEstimated primary completion: 26 Janua
 ry 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05557
 591
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06384807-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT06384807)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: A Phase 1/2 Study of BHV-1510 (
 Previously PBI-410) in Advanced Solid Tumors\nEstimated primary completion
 : February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemi
 plimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06384807
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06699602-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06699602)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A Study of Cemiplimab and Fianlim
 ab in People With Clear Cell Renal Cell Carcinoma\nEstimated primary compl
 etion: February 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06699602
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07404332-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT07404332)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: 5-Azacitidine Plus PD-1/PD-L1 Inh
 ibitor With PD-1/PD-L1 Refractory Tumors\nEstimated primary completion: 28
  February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemip
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07404332
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975152-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT04975152)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: Neoadjuvant Cemiplimab in Newly D
 iagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally 
 Advanced Cutaneous Squamous Cell Carcinoma\nEstimated primary completion: 
 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 975152
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855212-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06855212)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Phase II Study of Neoadjuvant Cet
 uximab and Cemiplimab in Patients Undergoing Surgery for HNSCC\nEstimated 
 primary completion: March 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06855212
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137054-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT05137054)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: A Study to Examine the Effects of
  Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments f
 or Adult Participants With Multiple Myeloma That is Resistant to Current S
 tandard of Care Treatments\nEstimated primary completion: 25 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05137054
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06902376-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT06902376)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: XL092 and Cemiplimab in BRAF WT T
 hyroid Cancer\nEstimated primary completion: 31 March 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06902376
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05694871-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280407
DTEND;VALUE=DATE:20280408
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT05694871)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Testing the Addition of Cemiplima
 b to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcom
 a\nEstimated primary completion: 7 April 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05694871
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418931-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07418931)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Mu
 lticenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy\, Sele
 cted on the Basis of Baseline Cytidine Deaminase Activity\, in Advanced Sq
 uamous Non-small Cell Lung Cancer\nEstimated primary completion: May 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07418931
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07234058-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07234058)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Trial Assessing Fianlimab Plus Ce
 miplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients Wit
 h Pleural Mesothelioma\nEstimated primary completion: May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07234058
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511036-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280524
DTEND;VALUE=DATE:20280525
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07511036)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: PROSECCO: A Phase 2\, 
 Single Arm\, Neoadjuvant Study Evaluating Combination Cemiplimab\, Fianlim
 ab\, And Ipilimumab In Patients With Surgically Resectable Melanoma\nEstim
 ated primary completion: 24 May 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07511036
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04543071-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT04543071)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Chemo4METPANC Combination Chemoki
 ne Inhibitor\, Immunotherapy\, and Chemotherapy in Pancreatic Adenocarcino
 ma\nEstimated primary completion: June 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04543071
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769698-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280604
DTEND;VALUE=DATE:20280605
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06769698)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A Study to See if Giving Fianlima
 b and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recu
 rrent or Metastatic Head and Neck Squamous Cell Carcinoma\nEstimated prima
 ry completion: 4 June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06769698
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06787612-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06787612)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Investigation of Ubamatamab Combi
 nation Therapy in Adult Participants With Platinum-Resistant Ovarian Cance
 r\nEstimated primary completion: 30 June 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06787612
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085572-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07085572)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Cemiplimab as Maintenance Treatme
 nt for Advanced Adrenocortical Cancer\nEstimated primary completion: July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07085572
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06790602-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06790602)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Cemiplimab Plus Gemcitabine in Pa
 tients With Metastatic Pancreatic Adenocarcinoma\nEstimated primary comple
 tion: July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemi
 plimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06790602
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07869823-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT07869823)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: Cemiplimab and Quad Shot Radiatio
 n for Cutaneous Squamous Cell Carcinoma in the Head and Neck\nEstimated pr
 imary completion: September 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07869823
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06656598-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06656598)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Adju
 vant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiother
 apy in Unfit or Elderly Patients With Stage III Lung Cancer\nEstimated pri
 mary completion: September 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06656598
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651593-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06651593)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Phase II Biomarker Study of BND-2
 2 in Combination With Cemiplimab in Solid Tumors\nEstimated primary comple
 tion: 1 September 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06651593
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06981325-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06981325)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Evaluation of Efficacy and Safety
  of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (
 BCC) Patients\nEstimated primary completion: October 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06981325
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385262-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06385262)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: TOP 
 2301: Neoadjuvant Chemo for NSCLC\nEstimated primary completion: 30 Octobe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063852
 62
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04590326-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281108
DTEND;VALUE=DATE:20281109
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT04590326)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: A Study to Find Out How Safe RE
 GN5668 is and How Well it Works In Adult Women When Given With Either Cemi
 plimab\, or Cemiplimab + Fianlimab\, or Ubamatamab\nEstimated primary comp
 letion: 8 November 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04590326
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669989-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT05669989)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: International Treatment-extension
  Study in Adult Participants With Multiple Myeloma and Who Have Derived Cl
 inical Benefit From Isatuximab\nEstimated primary completion: 30 November 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05669989
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07251413-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT07251413)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: Cemiplimab Plus Imiquimod and L
 aser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma\nE
 stimated primary completion: December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07251413
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101848-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07101848)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A PHASE II\, RANDOMIZED TRIAL TO 
 ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFT
 ER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCE
 R\nEstimated primary completion: December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07101848
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101822-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07101822)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A PHASE II\, RANDOMIZED STUDY TO 
 ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFT
 ER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCE
 R\nEstimated primary completion: December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07101822
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07360743-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07360743)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Immu
 notherapy Without Chemotherapy for Advanced Lung Cancer Patients With High
  PD-L1 Levels\nEstimated primary completion: December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07360743
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03017820-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT03017820)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: A Vaccine (VSV-hIFNβ-NIS) With o
 r Without Cyclophosphamide and Combinations of Ipilimumab\, Nivolumab\, an
 d Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma\, Acute M
 yeloid Leukemia or Lymphoma\nEstimated primary completion: 31 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT03017820
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508463-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT06508463)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: Intravenous Vesicular Stomatitis 
 Virus in Patients With Peripheral T-cell Lymphoma\nEstimated primary compl
 etion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06508463
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527325-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07527325)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: Fianlimab&Cemiplimab a
 s TotalNeoadj The (TNT) ForMelanoma\nEstimated primary completion: 1 Febru
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0752
 7325
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06874335-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT06874335)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: A Phase 1 Study of BHV-1530 in Ad
 vanced Solid Tumors\nEstimated primary completion: March 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06874335
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931717-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT06931717)
DESCRIPTION:Cemiplimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Cl
 inical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemipli
 mab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Hav
 e Not Received Prior Chemotherapy\nEstimated primary completion: March 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06931717
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06412198-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT06412198)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: A Multicenter Phase 1b/2 Study 
 of Adagrasib\, Cetuximab\, and Cemiplimab for Metastatic Colorectal Cancer
  Harboring KRAS G12C Mutations\nEstimated primary completion: 1 March 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06412198
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07058012-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290417
DTEND;VALUE=DATE:20290418
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07058012)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A Phase II Platform Study to Eval
 uate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or
  Other Novel Combinations in Patients With Colorectal Cancer With Minimal 
 Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)\nE
 stimated primary completion: 17 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07058012
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05878288-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT05878288)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Deep sequencIng in Cutaneous Squa
 mous CEll caRciNomas\nEstimated primary completion: May 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05878288
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07946848-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07946848)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebime
 tinib in Participants With Advanced or Metastatic NSCLC.\nEstimated primar
 y completion: May 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07946848
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06900595-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290602
DTEND;VALUE=DATE:20290603
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06900595)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Testing the Addition of an Anti-C
 ancer Drug\, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810)\
 , in Adolescents and Adults With Advanced Adrenocortical Cancer\nEstimated
  primary completion: 2 June 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06900595
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179315-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07179315)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A Study Comparing Two Immunothera
 py Options for Human Papillomavirus Positive HPV-Positive Head and Neck Ca
 ncer After Treatment\nEstimated primary completion: 30 November 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07179315
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188896-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07188896)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A Randomized Trial of Fianlimab a
 nd Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Ad
 vanced Renal Cell Carcinoma (RCC)\nEstimated primary completion: 30 Novemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07188
 896
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07808138-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07808138)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: RADI
 CAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly
  InOperable Stage I Non-small Cell Lung Cancer\nEstimated primary completi
 on: 1 December 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07808138
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465329-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291204
DTEND;VALUE=DATE:20291205
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06465329)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Pl
 us Other Cancer Treatments for Adult Patients With Operable Non-Small Cell
  Lung Cancer (NSCLC)\nEstimated primary completion: 4 December 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06465329
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07274384-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07274384)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Hype
 rprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial\nEst
 imated primary completion: 31 December 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07274384
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224022-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07224022)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Cemiplimab With Fianlimab for Res
 ectable Non-Metastatic Colon Cancer\nEstimated primary completion: 31 Dece
 mber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 24022
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387198-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07387198)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Neoadjuvant Merkel Cell Carcinoma
  Therapy (Tx) With the PD-1 Inhibitor Cemiplimab\nEstimated primary comple
 tion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07387198
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06219317-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06219317)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Immu
 notherapy Consolidation After Radical Treatment of Synchronous Oligo-metas
 tatic NSCLC\nEstimated primary completion: January 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06219317
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800015-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300116
DTEND;VALUE=DATE:20300117
SUMMARY:Cemiplimab: Phase 2/3 readout est. (NCT05800015)
DESCRIPTION:Cemiplimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemot
 herapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult 
 Patients With Advanced Non-small Cell Lung Cancer\nEstimated primary compl
 etion: 16 January 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05800015
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05142189-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT05142189)
DESCRIPTION:Cemiplimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Clin
 ical Trial Evaluating the Safety\, Tolerability and Preliminary Efficacy o
 f BNT116 Alone and in Combinations in Patients With Advanced Non-small Cel
 l Lung Cancer\nEstimated primary completion: February 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05142189
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413680-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300203
DTEND;VALUE=DATE:20300204
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT06413680)
DESCRIPTION:Cemiplimab\, phase 1/2\, Melanoma.\nStudy: A First-In Human (FI
 H) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combina
 tion With Cemiplimab Works in Adult Participants Who Have Cancer With Tumo
 rs That Have Spread in Their Body\nEstimated primary completion: 3 Februar
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064136
 80
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06205836-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06205836)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Cemiplimab With or Without Fianli
 mab to Treat Older Patients With Localized or Locally Advanced MSI-H Color
 ectal Cancer\nEstimated primary completion: May 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06205836
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06585410-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300503
DTEND;VALUE=DATE:20300504
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT06585410)
DESCRIPTION:Cemiplimab\, phase 3.\nStudy: Study of Intralesional Cemiplimab
  in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma\nEst
 imated primary completion: 3 May 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06585410
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06469281-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300527
DTEND;VALUE=DATE:20300528
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT06469281)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: A Study to Learn if 27T51\, a Muc
 in-16 (MUC16) Protein Targeting Immune Cell Therapy\, Administered Alone o
 r in Combination is Safe and How Well it Works for Adult Participants With
  Recurrent or Treatment Resistant Ovarian Cancers\nEstimated primary compl
 etion: 27 May 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 emiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06469281
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650266-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT07650266)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: A Study of Cemiplimab and Fianlim
 ab in People With Nasopharyngeal Carcinoma\nEstimated primary completion: 
 July 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 50266
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281768-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07281768)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Capecitabine/Oxaliplatin Chemothe
 rapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advan
 ced Rectal Cancer\nEstimated primary completion: July 2030. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07281768
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06418724-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06418724)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Neoadjuvant PD-1 Inhibitor and EG
 FR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma\nEstima
 ted primary completion: 30 July 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06418724
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07001618-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07001618)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Oral
  Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus B
 est Investigator's Choice in Patients With Resistance to Treatment Due to 
 Antibiotics Uptake With Advanced Non-small Cell Lung Cancer\nEstimated pri
 mary completion: September 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07001618
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746388-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07746388)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Adap
 tive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial\nEs
 timated primary completion: 1 September 2030. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07746388
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07470489-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07470489)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Zanzalintinib Plus Cemiplimab for
  the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer\nEstimated prim
 ary completion: 1 September 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07470489
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04428671-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301001
DTEND;VALUE=DATE:20301002
SUMMARY:Cemiplimab: Phase 1 readout est. (NCT04428671)
DESCRIPTION:Cemiplimab\, phase 1.\nStudy: Cemiplimab Before and After Surge
 ry for the Treatment of High Risk Cutaneous Squamous Cell Cancer\nEstimate
 d primary completion: 1 October 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04428671
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06848088-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301009
DTEND;VALUE=DATE:20301010
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06848088)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: A Study to Learn About
  the Long-Term Health of Adult Participants From a Previous Study of a New
  Melanoma Treatment\nEstimated primary completion: 9 October 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06848088
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594106-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301027
DTEND;VALUE=DATE:20301028
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT07594106)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: REGN15505 (PSMAx4-1BB) Alone or
  in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients W
 ith Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal C
 ell Carcinoma\nEstimated primary completion: 27 October 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07594106
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06121180-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06121180)
DESCRIPTION:Cemiplimab\, phase 2\, Melanoma.\nStudy: Study of Cemiplimab Pl
 us Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma\nEstimated 
 primary completion: 31 October 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06121180
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07808515-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301113
DTEND;VALUE=DATE:20301114
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07808515)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A Study Comparing Cemiplimab-base
 d Treatments for Adult Participants With Locally Advanced Basal Cell Skin 
 Cancer (laBCC)\nEstimated primary completion: 13 November 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07808515
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07050186-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301120
DTEND;VALUE=DATE:20301121
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07050186)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Cemiplimab for the Treatment of I
 ncurable Metastatic or Unresectable NUT Carcinoma\nEstimated primary compl
 etion: 20 November 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07050186
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: I-SPY TRIAL: Neoadjuvant and Pers
 onalized Adaptive Novel Agents to Treat Breast Cancer\nEstimated primary c
 ompletion: December 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT01042379
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918132-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301202
DTEND;VALUE=DATE:20301203
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06918132)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Cemi
 plimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non
 -Small Cell Lung Cancer\nEstimated primary completion: 2 December 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06918132
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281417-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20301216
DTEND;VALUE=DATE:20301217
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07281417)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Testing the Addition of Cemiplima
 b (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients 
 With Sinonasal Squamous Cell Carcinoma\nEstimated primary completion: 16 D
 ecember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemipli
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07281417
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07715734-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07715734)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Cemiplimab for Kidney Transplant 
 Recipients With Advanced Cutaneous Squamous Cell Carcinoma\nEstimated prim
 ary completion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07715734
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620548-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07620548)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Laser Interstitial Thermal Therap
 y (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas\
 nEstimated primary completion: 31 May 2031. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07620548
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07346196-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20310822
DTEND;VALUE=DATE:20310823
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07346196)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: A Trial of Locoregionally Advance
 d Squamous Cell Carcinoma of The Head and Neck\nEstimated primary completi
 on: 22 August 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 emiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07346196
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06917573-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06917573)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: PALA
 CE: Cemiplimab Trial According to ctDNA Levels\nEstimated primary completi
 on: 30 December 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06917573
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07433673-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07433673)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Gemcitabine\, Cisplatin\, Nab-pac
 litaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BT
 C)\nEstimated primary completion: January 2032. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07433673
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07943325-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20320229
DTEND;VALUE=DATE:20320301
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT07943325)
DESCRIPTION:Cemiplimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Dela
 yed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell
  Lung Cancer\nEstimated primary completion: February 2032. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07943325
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07567469-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20320827
DTEND;VALUE=DATE:20320828
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT07567469)
DESCRIPTION:Cemiplimab\, phase 1/2.\nStudy: A Safety and Efficacy Study of 
 Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurren
 t or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma\nEstima
 ted primary completion: 27 August 2032. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07567469
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07195734-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20330201
DTEND;VALUE=DATE:20330202
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07195734)
DESCRIPTION:Cemiplimab\, phase 2.\nStudy: Testing the Addition of Chemother
 apy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck
  Cancer\nEstimated primary completion: 1 February 2033. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07195734
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720167-1975@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20350801
DTEND;VALUE=DATE:20350802
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07720167)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Cemi
 plimab for Clinical Stage I\, 2-3.9cm\, Non-Small Cell Lung Cancer\nEstima
 ted primary completion: 1 August 2035. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07720167
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
